Summary
Nineteen patients with advanced, previously treated breast cancer received treatment with vincristine 2 mg i.v., mitomycin-C 6 mg/m2 and mitoxantrone (Novantrone®; dihydroxyanthracenedione) 12 mg/m2 i.v. every three weeks. Thirteen patients are evaluable for response and toxicity. Partial remission was seen in six patients, with soft tissue, bone and visceral metastases and static disease in a further four patients. Median duration of response has not yet been reached (8+ months). Toxicity was mild and predictable, with no patient experiencing severe nausea and vomiting, and only four of the patients requiring a wig for alopecia. Malaise and lethargy were common in those patients receiving more than three courses, and an increase in the mean corpuscular volume (MCV) together with a fall in haemoglobin were seen in patients receiving multiple courses of treatment. The study suggests that this combination is active, and may prove useful with other agents in the treatment of breast cancer.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Carbone PP: Breast cancer. In HM Pinedo and BA Chabner (eds): The EORTC Cancer Chemotherapy Annual 5. Elsevier, Amsterdam, 1983, pp398–422
Smalley RV, Lefante J, Bartolucci A: CAF vs CMFVP in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:444, 1981
Godrey TE: Mitomycin-C in breast cancer. In SK Carter and ST Crooke (eds): Mitomycin-C — Current Status and New Developments. Academic Press, New York, 1979, pp91–100
Davis TE, Carbone PP: Drug treatment of breast cancer. Drugs 16:441, 1978
Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE: Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12:1–4, 1984
Coleman RE, Rubens RD, Knight RK, Maisey MN: Mitoxantrone in advanced breast cancer — a phase II study with special attention to cardiotoxicity. Br J Cancer 49:390, 1984
Neidhart JA, Gochnour D, Young DC: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomised cross-over trial. Cancer Treat Rev 10 (Suppl B):47–52, 1983
Oster MW, Park Y, Grossbard L: Vincristine (V) and mitomycin (M) therapy for previously treated breast cancer. Proc Am Soc Clin Oncol 22:448, 1981
World Health Organisation: WHO handbook for reporting results of cancer treatment. WHO offset publication no.48, Geneva, 1979
Crossley RJ: Clinical safety and tolerance of mitoxantrone (Novantrone). Cancer Treat Rev 10 (Suppl B):29–36, 1983
Pavy MD, Wiely EL, Abeloff MD: Haemolytic-uraemic syndrome associated with mitomycin therapy. Cancer Treat Rep 66:457, 1982
Baker LH, Vaitkevicius VK: The development of an acute intermittent schedule — Mitomycin-C. In SK Carter and ST Crooke (eds): Mitomycin-C — Current Status and New Developments. Academic Press, New York, 1979, pp77–82
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Perren, T.J., Blackledge, G., Mould, J.J. et al. Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity. Invest New Drugs 3, 173–177 (1985). https://doi.org/10.1007/BF00174166
Issue Date:
DOI: https://doi.org/10.1007/BF00174166